Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-mis-shaped (nonanaplastic) thyroid cancer that came from follicle cells, and it has spread or cannot be removed with surgery
- Your tumor must have a known RET gene fusion found on approved lab testing (tissue or blood sample)
- Your cancer must be “radioactive-iodine resistant” based on whole-body scan results and/or scan progression despite prior iodine treatment
- You must have at least one measurable spot of cancer on scans (tumor size/visibility rules apply) and no single tumor deposit over 4 cm
- You can’t have had too much prior radioactive iodine treatment (total treatment dose must be 500 mCi or less)
- You must be healthy enough for treatment (meeting lab and heart/conce rns rules) and able to swallow the study pills
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This trial tests a targeted drug (a RET inhibitor) taken before surgery to help shrink thyroid cancer that has a specific genetic change (RET alteration). It may make surgery easier or more successful.
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
This trial tests whether the combination of cyclophosphamide and sirolimus can slow or shrink metastatic thyroid cancer that does not respond to iodine-131. It may help people whose cancer can’t be cured with surgery or other standard options and is still growing.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
This Phase 1 study tests how doctors plan a combination of two radiation approaches—external beam radiation and radioactive iodine—for thyroid cancer that is not fully responding to standard treatment. It may help people who still have iodine-avid tumor spots, but whose iodine uptake looks too low to work well with radioactive iodine alone.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.